<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; DexCom Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/dexcom-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(DXCM) DexCom Misses Analyst Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/05/dxcm-dexcom-misses-analyst-estimates/73288</link>
		<comments>http://www.stockbloghub.com/2011/05/05/dxcm-dexcom-misses-analyst-estimates/73288#comments</comments>
		<pubDate>Thu, 05 May 2011 15:47:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[DexCom Inc]]></category>
		<category><![CDATA[DXCM]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73288</guid>
		<description><![CDATA[DexCom (DXCM), a prominent player in the glucose monitoring market, reported first-quarter fiscal 2011 loss per share of 19 cents, a penny higher than  the Zacks Consensus Estimate while sharply less than the year-ago loss of 40 cents per share. Net loss for the quarter trimmed roughly 41.5% year over year to $11.9 million owing to a healthy revenue growth. Revenues Revenues for the quarter shot up roughly 48.5% year over year to $14.2 million, still missing the Zacks Consensus Estimate of $15 million. Product sales almost doubled year over year to $13.1 million while development grant and other revenues dropped 62.8% to slightly over $1 million. Margins and Expenses Gross margin for the quarter dipped slightly to 36.1% from 36.2% a year ago. Operating expenses leaped 16.9% year over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/dxcm-dexcom-misses-analyst-estimates/73288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DXCM) DexCom Earnings Report Meets The Street but Sales Miss</title>
		<link>http://www.stockbloghub.com/2010/11/24/dxcm-dexcom-earnings-report-meets-the-street-but-sales-miss/58508</link>
		<comments>http://www.stockbloghub.com/2010/11/24/dxcm-dexcom-earnings-report-meets-the-street-but-sales-miss/58508#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:57:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[DexCom Inc]]></category>
		<category><![CDATA[DXCM]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58508</guid>
		<description><![CDATA[DexCom (DXCM) reported third-quarter 2010 loss per share of 23 cents, matching the Zacks Consensus Estimate and improving from the year-ago loss of 29 cents. Revenues Total revenue (consisted of “Product revenue” and “Development grant and other revenue”) rose 61% year over year to $11.7 million in the reported quarter, missing the Zacks Consensus Estimate of $14 million. Product sales soared 133% year over year to $10.8 million while development grant and other revenue plummeted 66% to $0.9 million. Margin Gross margin improved sharply to 29.8% from 11.9% in the year-ago quarter. Operating margin remained in the red at -112%, an improvement nonetheless from -159.5% in the prior-year quarter. Balance Sheet As of September 30, 2010, the company had $29.9 million in cash and short-term marketable securities, available for sale, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/dxcm-dexcom-earnings-report-meets-the-street-but-sales-miss/58508/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DXCM) DexCom Analyst Reiterates Stock at Neutral</title>
		<link>http://www.stockbloghub.com/2010/08/26/dxcm-dexcom-analyst-reiterates-stock-at-neutral/49346</link>
		<comments>http://www.stockbloghub.com/2010/08/26/dxcm-dexcom-analyst-reiterates-stock-at-neutral/49346#comments</comments>
		<pubDate>Thu, 26 Aug 2010 16:45:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[DexCom Inc]]></category>
		<category><![CDATA[DXCM]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49346</guid>
		<description><![CDATA[We reaffirm our Neutral recommendation on DexCom Inc (DXCM), a prominent player in the continuous glucose monitoring market. Second-quarter fiscal 2010 loss per share of 20 cents matched the Zacks Consensus Estimate while revenues soared 75% year-over-year riding on solid product sales. DexCom is a medical devices company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. We believe DexCom is well positioned to gain a significant share of the glucose monitoring market. The diabetes market is large and growing. An important component of effective diabetes management is frequent monitoring of blood glucose levels. DexCom’s product has a comparative advantage in terms of both patient convenience and quality ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/26/dxcm-dexcom-analyst-reiterates-stock-at-neutral/49346/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DXCM) DexCom Quarterly Loss Higher Than Expected</title>
		<link>http://www.stockbloghub.com/2010/05/13/dxcm-dexcom-quarterly-loss-higher-than-expected/37116</link>
		<comments>http://www.stockbloghub.com/2010/05/13/dxcm-dexcom-quarterly-loss-higher-than-expected/37116#comments</comments>
		<pubDate>Thu, 13 May 2010 20:40:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[DexCom Inc]]></category>
		<category><![CDATA[DXCM]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37116</guid>
		<description><![CDATA[DexCom, Inc. (DXCM) reported a loss of 27 cents per share in the first quarter, 3 cents above the Zacks Consensus Estimate of a loss of 24 cents but well below the year-ago loss of 33 cents. Revenues came in at $9.5 million, up 83% from the $5.2 million reported in the year-ago period. Total revenue consists of product revenue and development grant revenue. Development grant revenue came in at $2.8 million. Product revenue increased 153% to $6.8 million for the first quarter of 2010. On a sequential basis, product revenue increased 2%. During the reported quarter, the company sold approximately 2,600 systems. The slight sequential growth in product revenues was expected as the first quarter is traditionally a seasonally slow quarter in the durable medical equipment business. Product cost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/13/dxcm-dexcom-quarterly-loss-higher-than-expected/37116/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DXCM) DexCom Reports Smaller Loss on Increased Revenues</title>
		<link>http://www.stockbloghub.com/2010/03/12/dxcm-dexcom-reports-smaller-loss-on-increased-revenues/30466</link>
		<comments>http://www.stockbloghub.com/2010/03/12/dxcm-dexcom-reports-smaller-loss-on-increased-revenues/30466#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:38:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[DexCom Inc]]></category>
		<category><![CDATA[DXCM]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30466</guid>
		<description><![CDATA[DexCom, Inc. (DXCM) reported a net loss of 25 cents per share in the fourth quarter of 2009, a couple cents narrower than the Zacks Consensus Estimate for a net loss of 27 cents and significantly narrower than the year-ago net loss of 49 cents. The significant improvement in financial results was due to higher revenues. Full year net loss came in at $1.21, well below the year-ago net loss of $2.00. Revenues increased 202% to $29.7 million, with product revenues increasing 122% to $18 million. The Quarter in Detail Fourth-quarter revenues came in at $10.5 million, up 157% from the $4.1 million reported in the year-ago period. Total revenues consist of product revenues and development grant revenues. Development grant revenues came in at $3.8 million. This included milestone revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/dxcm-dexcom-reports-smaller-loss-on-increased-revenues/30466/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DXCM) DexCom SEC Filing Reports Product Revenues</title>
		<link>http://www.stockbloghub.com/2010/01/18/dxcm-dexcom-sec-filing-reports-product-revenues/25203</link>
		<comments>http://www.stockbloghub.com/2010/01/18/dxcm-dexcom-sec-filing-reports-product-revenues/25203#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:18:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[DexCom Inc]]></category>
		<category><![CDATA[DXCM]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25203</guid>
		<description><![CDATA[In a filing with the U.S. Securities and Exchange Commission (SEC), DexCom, Inc. (DXCM) recently stated that it expects unaudited product revenues of approximately $6.6 million for the fourth quarter of 2009. This represents a 43% sequential increase from the product revenues reported by the company in the third quarter of 2009. DexCom reported that it sold approximately 2,800 starter kits during the fourth quarter of 2009, representing a sequential increase of about 31% in starter kit sales. Sensor revenues were up about 50% on a sequential basis. DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. According to the Centers for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/dxcm-dexcom-sec-filing-reports-product-revenues/25203/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DXCM) DexCom Incorporated&#8217;s Loss Narrows</title>
		<link>http://www.stockbloghub.com/2009/11/14/dxcm-dexcom-incorporateds-loss-narrows/20521</link>
		<comments>http://www.stockbloghub.com/2009/11/14/dxcm-dexcom-incorporateds-loss-narrows/20521#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:25:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[DexCom Inc]]></category>
		<category><![CDATA[DXCM]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20521</guid>
		<description><![CDATA[DexCom, Inc. (DXCM) reported a net loss of 29 cents per share in the third quarter, 3 cents below the Zacks Consensus Estimate of a net loss of 32 cents and significantly below the year-ago net loss of 53 cents. The significant improvement in financial results was due to higher revenue. Revenue came in at $7.3 million, up 278% from the $1.9 million reported in the year-ago period. Total revenue consists of product revenue and development grant revenue. Development grant revenue came in at $2.6 million. Product revenue increased 146% to $4.6 million for the third quarter of 2009. On a sequential basis, product revenue increased 12%. During the reported quarter, DexCom sold approximately 2,125 systems representing a sequential increase of 10%. Product cost of sales increased $1 million to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/dxcm-dexcom-incorporateds-loss-narrows/20521/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

